| Acquirer | Target | Price |
|---|---|---|
| Mylan N.V. | Renaissance's generics business | $950 million |
| Daiichi Sankyo | License to Heartcel™ in Japan | $14.28 million |
| Incyte Corporation | Ariad's European operations | $140 million |
| Chiesi Farmaceutici SpA | Cardiovascular drug line | $260 million |
| Vifor Frensius Medical Care Renal Pharma Ltd. | Rights to RAYALDEE® | $50 million |
Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
